Scitop Bio released its 2021 annual report, which shows that the company achieved operating revenue of about RMB 365 million yuan (USD $54.75 million) in 2021, with an increase of 7.51% year-on-year. In addition, the performance of the company’s edible probiotic products segment was so stunning that the business revenue in 2021 increased by 128.63% year-on-year, and the revenue share also increased from 1.08% in 2017 to one-fifth of the overall revenue share in 2021.
Up to now, Scitop Bio obtain 95 patents and many non-patent technologies related to probiotics, and has built the largest lactic acid bacteria strain resource library in Asia, among which more than 120 strains of probiotics have been industrialized. During the reporting period, the company has systematically carried out 34 R&D projects. (Source: finance.eastmoney)
Visit HPA-China’s Information Hub, CLICK HERE